德勤:首季香港新股集資額跌至第五位 宗數持平
德勤中國表示,今年首季香港新股市場延續去年全年的暢旺氣氛,新股上市宗數與去年持平,達37宗,維持全球第一,但受新型肺炎疫情影響,有部分公司延遲上市計劃,期內未出現大型上市個案,主板新股平均規模按年跌38%至4億元,令首季新股集資額按年下跌31%至141億元,排全球第5位;首位則為集資765億元的上海交易所。
內地市場方面,新股數量與融資額均按年大幅增長,由2019年第一季度的31隻新股融資256億元人民幣,增加至期內總共有51隻新股融資781億元人民幣,增幅分別為65%與205%;當中有三分之一集資額來自新推出的科創板。
赴美上市的中概股數量持平,但類型則由去年的金融機構及券商為主,轉為醫藥及生物科技公司,集資額亦增加42%至3.7億美元。
問到中概股瑞幸咖啡捲入假帳事件,華南區主管合夥人兼全國上市業務組聯席主管合夥人歐振興表示,美國市場監管一向嚴格,相信未會因此事件影響到未來中概股的上市申請;但指出自3月美股觸發熔斷機制後未再有中資企業在當地上市,相信企業目前會較審慎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.